An International, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)
An International, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)
The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC) on arrhythmia-related cardiovascular outcomes in participants on chronic hemodialysis with recurrent hyperkalemia.
This is an international, multicenter, event-driven, randomized, double-blind, parallel group, placebo-controlled study, evaluating the utility of SZC versus placebo to reduce the incidence of sudden cardiac death (SCD), stroke, and arrhythmia-related hospitalizations, interventions, and emergency department (ED) visits in participants on chronic hemodialysis with recurrent hyperkalemia.
Inclusion Criteria:
Exclusion Criteria:
Taian, 271099, China
Dhanvantari Nagar, 605006, India
Fujisawa-shi, 251-0041, Japan
Kawasaki-shi, 210-0852, Japan
Kumagaya-shi, 360-0831, Japan
Moriya-shi, 3020118, Japan
Nakagami-gun, 901-2393, Japan
Okinawa-shi, 904-2143, Japan
Sashima-gun, 306-0433, Japan
Setagaya-ku, 158-0094, Japan
Shiroishi-shi, 989-0231, Japan
Toride-shi, 302-0011, Japan
Tsuchiura-shi, 300-0062, Japan
Tsuchiura-shi, 300-0835, Japan
Ushiku-shi, 300-1296, Japan
Yatomi-shi, 498-0006, Japan
D.F, 14000, Mexico
Mytischi, 141009, Russia
Chernivtsі, 58001, Ukraine